[ Editor’s Note: Welcome to what you get when a crime family gets control of the White house. This is just another page in this sordid chapter that because the President is completely immune for everything he does as president, then that is a green flag for presidential family looting.
Will the Trump family see any of the now expected high profits that the drug companies make selling this drug at hundreds of times its cost to produce?…Jim W Dean ]
THE FEDERAL GOVERNMENT has failed to include intellectual property and pricing protections in at least four contracts for drugs to combat Covid-19.
Legal safeguards meant to ensure that products developed with federal funds are affordable and widely available were missing from the contracts, which are worth more than $1 billion and were released along with other documents last week in response to freedom of information requests. The omissions make it more likely that potentially lifesaving treatments and vaccines may be priced out of reach, even as the spiraling financial and health crises increase the need for affordable drugs.
Standard federal contracts ensure that inventions developed with government funding are available to the public “on reasonable terms.” But the four agreements for Covid-19-related products — three of which were made by a division of the Department of Health and Human Services known as the Biomedical Advanced Research and Development Authority, or BARDA, and one of which was made with the Department of Defense — notably omitted the phrase “on reasonable terms.” The government contracts with pharmaceutical companies Janssen, Regeneron, Genentech, and Ology Bioservices also limit the government’s patent rights to the products being developing for Covid-19, even though they are using taxpayer dollars to do so.